On January 29, 2026 Syntara Limited (ASX: SNT), a clinical-stage drug development company, reported a summary of its activities for the quarter ended 31 December 2025:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Lead asset amsulostat continues to build momentum
Amsulostat clinical and preclinical data presented at American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in Orlando
Second myelodysplastic syndrome (MDS) study initiated with launch of amsulostat Phase 2 Australian MESSAGE trial in transfusion-dependent low and intermediate risk patients
Positive European Medicines Agency opinion received for Orphan Drug Designation of amsulostat in myelofibrosis
Pancreatic cancer Phase 1/2 clinical trial of amsulostat in collaboration with the Garvan, funded by MRFF, announced post quarter end
Pipeline assets progress
SNT-4728 Phase 2 iRBD trial fully recruited with data expected in Q2 2026, triggering payment of $1.8 million expected in Q1 2026
Progression of topical anti-fibrotic SNT-9465 into hypertrophic scar study following successful completion of Phase 1a study
Proforma cash balance at 31 December of $12.3 million.
Syntara CEO Gary Phillips said: "2026 is shaping up to be a pivotal year for Syntara, with five separate data read-outs expected across the Company’s clinical portfolio, each capable of materially advancing both value and strategic optionality.
In haematology, the initiation of the Phase 2 MESSAGE trial in transfusiondependent MDS represents a further expansion for amsulostat (SNT-5505), backed by strong external validation through the Australasian Leukaemia & Lymphoma Group (ALLG) and non-dilutive support from the Medical Research Future Fund. I’m excited to see if the compelling pre-clinical data for amsulostat in MDS translates into the clinic. By mid-2026 we should see preliminary data from this study and the MDS trial in a high risk population being run in Germany that extends the drug’s utility more widely across myeloproliferative neoplasms.
Across the broader pipeline, our topical anti fibrotic, SNT-9465, has progressed into a three-month study treating patients with sternotomy scars following a successful first-in-human study, with results expected in 2026 alongside the ongoing SATELLITE keloid pilot study. We received a lot of positive feedback about the KOL skin scarring webinar we ran with Prof Ardeshir Bayat in November. It was inspiring to hear from a renowned leader in the field of scarring really unpack what is going on in an abnormal scarring process. His explanation about how our pan-LOX inhibitor can potentially "unlock the scar" and lead to permanent improvements in appearance and function is all the motivation we need to accelerate the development of this element of our pipeline.
Meanwhile our neuroinflammatory targeting drug, SNT-4728, has now completed recruitment in its Phase 2 iRBD trial with top-line results expected in Q2 2026. This result is keenly anticipated by our partners in the field of Parkinson’s Disease research and adds to the compelling cadence of catalysts that positions 2026 as a defining year for the Company."
(Press release, Syntara, JAN 29, 2026, https://mcusercontent.com/add2e2fa70ec3d0eeaf2a93cc/files/dc90a199-0b91-520d-956a-91abeb3a25cc/2A1650256_SNT.pdf [SID1234662332])